We are live on ! Find out more
BCM

Boxer Capital Management Portfolio holdings

AUM $1.33B
1-Year Est. Return 864.5%
This Fund
S&P 500
This Quarter Est. Return
+49.54%
1 Year Est. Return
+864.5%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.33B
AUM Growth
+$566M
Cap. Flow
+$243M
Cap. Flow %
18.34%
Top 10 Hldgs %
65.15%
Holding
66
New
12
Increased
17
Reduced
1
Closed
3

Top Buys

Rank Stock Value
1
ABVX
Abivax
ABVX
+$45.8M
2
QTTB icon
Q32 Bio
QTTB
+$26.3M
3
CAPR icon
Capricor Therapeutics
CAPR
+$24.4M
4
CELC icon
Celcuity
CELC
+$22.1M
5
QURE icon
uniQure
QURE
+$22M

Top Sells

Rank Stock Value
1
TERN
Terns Pharmaceuticals
TERN
+$19.8M
2
SLNO
Soleno Therapeutics
SLNO
+$6.7M
3
ALLO icon
Allogene Therapeutics
ALLO
+$2.69M
4
KALV
KalVista Pharmaceuticals
KALV
+$411K

Sector Composition

Rank Sector Weight
1 Healthcare 99.78%
2 Consumer Staples 0.22%
3 Miscellaneous 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TNGX icon
1
Tango Therapeutics
TNGX
$3.94B
$340M 25.61%
10,876,219
– –
RVMD icon
2
Revolution Medicines
RVMD
$44.6B
$93.6M 7.05%
500,000
– –
ABVX
3
Abivax
ABVX
$9.89B
$80.6M 6.07%
605,000
+405,000
+203% +$45.8M
QURE icon
4
uniQure
QURE
$3.38B
$69.2M 5.21%
1,503,300
+841,300
+127% +$22M
KOD icon
5
Kodiak Sciences
KOD
$2.37B
$57.6M 4.34%
1,477,600
+116,600
+9% +$4.54M
KYMR icon
6
Kymera Therapeutics
KYMR
$9.82B
$49.2M 3.71%
429,100
+100,000
+30% +$8.59M
DFTX
7
Definium Therapeutics
DFTX
$5.51B
$47M 3.54%
998,500
+400,000
+67% +$9.88M
REPL icon
8
Replimune Group
REPL
$1.46B
$44.1M 3.32%
3,983,000
+2,808,000
+239% +$17.2M
CELC icon
9
Celcuity
CELC
$4.33B
$43.6M 3.28%
416,530
+191,530
+85% +$22.1M
QTTB icon
10
Q32 Bio
QTTB
$447M
$40.1M 3.02%
+3,149,310
New +$26.3M
CAPR icon
11
Capricor Therapeutics
CAPR
$558M
$33.6M 2.53%
1,395,156
+805,156
+136% +$24.4M
PGEN icon
12
Precigen
PGEN
$2.49B
$29.4M 2.21%
5,150,000
+1,650,000
+47% +$7.13M
CORT icon
13
Corcept Therapeutics
CORT
$12.3B
$29.2M 2.2%
335,500
+85,500
+34% +$5.16M
SRZN icon
14
Surrozen
SRZN
$264M
$27M 2.03%
1,105,683
+339,365
+44% +$9.32M
PTGX icon
15
Protagonist Therapeutics
PTGX
$9.34B
$20.8M 1.57%
170,000
– –
VIR icon
16
Vir Biotechnology
VIR
$1.83B
$19M 1.43%
1,866,000
– –
PCVX icon
17
Vaxcyte
PCVX
$8.9B
$18.9M 1.42%
325,000
– –
URGN icon
18
UroGen Pharma
URGN
$2.13B
$18.4M 1.39%
500,000
– –
CRVS icon
19
Corvus Pharmaceuticals
CRVS
$1.19B
$16.4M 1.24%
1,100,000
– –
PTCT icon
20
PTC Therapeutics
PTCT
$5.85B
$16.3M 1.23%
200,000
– –
PRAX icon
21
Praxis Precision Medicines
PRAX
$9.63B
$15.6M 1.17%
46,457
– –
AMLX icon
22
Amylyx Pharmaceuticals
AMLX
$3.87B
$14.4M 1.08%
800,000
– –
OCUL icon
23
Ocular Therapeutix
OCUL
$2.28B
$12.8M 0.96%
1,300,000
+950,000
+271% +$8.61M
IRD
24
Opus Genetics
IRD
$307M
$11.6M 0.87%
2,815,000
+565,000
+25% +$2.64M
PALI icon
25
Palisade Bio
PALI
$349M
$10M 0.76%
4,799,875
– –
1
2 3

Similar funds

BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.33B AUM 29.71% 1-Year Est. Return
GAB
German American Bancorp Jasper, Indiana $1.33B AUM 37.42% 1-Year Est. Return
MIC
Means Investment Company Bangor, Maine $1.32B AUM 24.33% 1-Year Est. Return
CA
Cullinan Associates Louisville, Kentucky $1.32B AUM 30.92% 1-Year Est. Return
OCM
Ovata Capital Management Hong Kong $1.33B AUM 5.69% 1-Year Est. Return
GAMA
Graticule Asia Macro Advisors New York $1.33B AUM 1,044.61% 1-Year Est. Return
CCM
Condor Capital Management Martinsville, New Jersey $1.33B AUM 19.79% 1-Year Est. Return

Boxer Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Boxer Capital Management held 66 positions worth $1.33B, up 74% from $762M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Boxer Capital Management deployed $243M of net new capital in Q2 2026, opening 12 new positions and adding to 17 existing holdings. Its largest new stake was Q32 Bio: 3,149,310 shares worth $40.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Consumer Staples and Miscellaneous.

On the sell side, the largest reduction was Allogene Therapeutics, an estimated $2.69M trimmed.

  • Boxer Capital Management's largest Q2 2026 buy was Q32 Bio: 3,149,310 shares worth $40.1M.
  • Boxer Capital Management added most to Abivax in Q2 2026, an estimated $45.8M increase.
  • Boxer Capital Management's biggest Q2 2026 reduction was Allogene Therapeutics, cutting an estimated $2.69M.
  • Boxer Capital Management fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $19.8M.
  • Boxer Capital Management's ten largest holdings make up 65% of its $1.33B portfolio in Q2 2026.
  • Boxer Capital Management opened 12 new positions and closed 3 in Q2 2026.
  • Boxer Capital Management's portfolio value rose 74% quarter-over-quarter to $1.33B.

Based on Boxer Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.